

# Matthias Augustin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4323750/publications.pdf>

Version: 2024-02-01

438  
papers

16,682  
citations

18482

62  
h-index

30922

102  
g-index

522  
all docs

522  
docs citations

522  
times ranked

9141  
citing authors

#	ARTICLE	IF	CITATIONS
1	National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. <i>BMJ</i> , The, 2020, 369, m1590.	6.0	479
2	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet</i> , The, 2018, 392, 650-661.	13.7	457
3	Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus. <i>Acta Dermato-Venereologica</i> , 2012, 92, 502-507.	1.3	379
4	Epidemiology and comorbidity of psoriasis in children. <i>British Journal of Dermatology</i> , 2010, 162, 633-636.	1.5	375
5	Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus. <i>Acta Dermato-Venereologica</i> , 2012, 92, 497-501.	1.3	347
6	Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2009, 160, 1040-1047.	1.5	341
7	Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany. <i>Acta Dermato-Venereologica</i> , 2010, 90, 147-151.	1.3	265
8	Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany. <i>Dermatology</i> , 2008, 216, 366-372.	2.1	237
9	S3 " Guidelines on the treatment of psoriasis vulgaris (English version). Update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, S1-95.	0.8	235
10	Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1148-1158.	2.4	209
11	Psoriasis: is the impairment to a patient's life cumulative?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 989-1004.	2.4	180
12	Measuring Change in Quality of Life: Bias in Prospective and Retrospective Evaluation. <i>Value in Health</i> , 2015, 18, 110-115.	0.3	177
13	Epidemiology of chronic wounds in Germany: Analysis of statutory health insurance data. <i>Wound Repair and Regeneration</i> , 2016, 24, 434-442.	3.0	170
14	Comparison of Biologics and Oral Treatments for Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 258.	4.1	169
15	Prevalence of skin lesions and need for treatment in a cohort of 90880 workers. <i>British Journal of Dermatology</i> , 2011, 165, 865-873.	1.5	166
16	Cost of illness of chronic leg ulcers in Germany. <i>International Wound Journal</i> , 2010, 7, 97-102.	2.9	165
17	Prevalence of Chronic Pruritus in Germany: Results of a Cross-Sectional Study in a Sample Working Population of 11,730. <i>Dermatology</i> , 2010, 221, 229-235.	2.1	165
18	Nail psoriasis in Germany: epidemiology and burden of disease. <i>British Journal of Dermatology</i> , 2010, 163, 580-585.	1.5	160

#	ARTICLE	IF	CITATIONS
19	Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 683-691.	2.4	159
20	The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. <i>Archives of Dermatological Research</i> , 2009, 301, 561-571.	1.9	151
21	European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1059-1065.	2.4	150
22	Adherence in the Treatment of Psoriasis: A Systematic Review. <i>Dermatology</i> , 2011, 222, 363-374.	2.1	146
23	Telemedicine in dermatology: findings and experiences worldwide – a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 215-224.	2.4	143
24	Prevalence of Skin Diseases in a Cohort of 48,665 Employees in Germany. <i>Dermatology</i> , 2008, 217, 169-172.	2.1	141
25	Pruritus Assessment in Clinical Trials: Consensus Recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. <i>Acta Dermato-Venereologica</i> , 2013, 93, 509-514.	1.3	141
26	Willingness-to-pay and quality of life in patients with vitiligo. <i>British Journal of Dermatology</i> , 2009, 161, 134-139.	1.5	135
27	Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. <i>Dermatology</i> , 2015, 231, 35-40.	2.1	126
28	The –Wound–QoL–: A short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. <i>Wound Repair and Regeneration</i> , 2014, 22, 504-514.	3.0	125
29	Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. <i>Archives of Dermatological Research</i> , 2015, 307, 875-883.	1.9	124
30	Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. <i>British Journal of Dermatology</i> , 2014, 171, 1123-1128.	1.5	120
31	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 266-276.e5.	1.2	117
32	Cost-of-illness of leg ulcers in the community. <i>International Wound Journal</i> , 2014, 11, 283-292.	2.9	112
33	Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study. <i>Dermatology</i> , 2006, 212, 137-144.	2.1	109
34	Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. <i>British Journal of Dermatology</i> , 2010, 162, 661-668.	1.5	108
35	S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 645-669.	0.8	107
36	Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 1-119.	0.8	104

#	ARTICLE	IF	CITATIONS
37	German S3-guidelines on the treatment of psoriasis vulgaris (short version). Archives of Dermatological Research, 2012, 304, 87-113.	1.9	96
38	Willingness to pay and quality of life in patients with atopic dermatitis. Archives of Dermatological Research, 2014, 306, 279-286.	1.9	96
39	Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 309-313.	2.4	96
40	Cost of illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. JDDG - Journal of the German Society of Dermatology, 2005, 3, 511-518.	0.8	92
41	Patient-relevant treatment goals in psoriasis. Archives of Dermatological Research, 2016, 308, 69-78.	1.9	92
42	Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. European Journal of Dermatology, 2010, 20, 062-067.	0.6	88
43	Quality of life in psoriasis patients. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 559-568.	1.4	88
44	Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: A multicenter study. JDDG - Journal of the German Society of Dermatology, 2007, 5, 209-218.	0.8	87
45	Effectiveness of Advanced versus Conventional Wound Dressings on Healing of Chronic Wounds: Systematic Review and Meta-Analysis. Dermatology, 2013, 226, 172-184.	2.1	85
46	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. British Journal of Dermatology, 2019, 181, 954-966.	1.5	84
47	Cross-Cultural Inequivalence of Dermatology-Specific Health-Related Quality of Life Instruments in Psoriasis Patients. Journal of Investigative Dermatology, 2007, 127, 2315-2322.	0.7	80
48	Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 700-708.	2.4	78
49	Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit. American Journal of Clinical Dermatology, 2016, 17, 163-169.	6.7	77
50	Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 151-157.	2.4	77
51	Prevalence and Disease Burden of Hyperhidrosis in the Adult Population. Dermatology, 2013, 227, 10-13.	2.1	76
52	Prevalence, predictors and comorbidity of dry skin in the general population. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 147-150.	2.4	72
53	Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. British Journal of Dermatology, 2009, 161, 1143-1148.	1.5	71
54	German Adaptation of the Skindex-29 Questionnaire on Quality of Life in Dermatology: Validation and Clinical Results. Dermatology, 2004, 209, 14-20.	2.1	70

#	ARTICLE	IF	CITATIONS
55	Methods of Outcomes Measurement in Nail Psoriasis. <i>Dermatology</i> , 2010, 221, 23-28.	2.1	67
56	Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1195-1203.	2.4	67
57	S3 - Guidelines on the treatment of psoriasis vulgaris Update 2011. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, S1-S95.	0.8	66
58	Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. <i>Archives of Dermatological Research</i> , 2012, 304, 433-441.	1.9	66
59	Tailoring the Cut-off Values of the Visual Analogue Scale and Numeric Rating Scale in Itch Assessment. <i>Acta Dermato-Venereologica</i> , 2017, 97, 759-760.	1.3	65
60	A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. <i>British Journal of Dermatology</i> , 2018, 179, 173-181.	1.5	64
61	Diagnosis and treatment of xerosis cutis – a position paper. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 3-33.	0.8	64
62	Quality of psoriasis care in Germany – results of the national study PsoHealth 2007. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008, 6, 640-645.	0.8	63
63	German psoriasis registry PsoBest: objectives, methodology and baseline data. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 48-57.	0.8	63
64	PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 1210-7.	0.8	63
65	Validation and Clinical Results of the FLQA-d, a Quality of Life Questionnaire for Patients with Chronic Skin Disease. <i>Dermatology and Psychosomatics</i> , 2000, 1, 12-17.	0.1	62
66	Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 576-585.	2.4	62
67	S2k guideline on diagnosis and treatment of atopic dermatitis – short version. <i>Allergo Journal International</i> , 2016, 25, 82-95.	2.0	60
68	Quality of life evaluation in wounds: validation of the Freiburg Life Quality Assessment-wound module, a disease-specific instrument. <i>International Wound Journal</i> , 2010, 7, 493-501.	2.9	59
69	Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 457-463.e5.	1.2	58
70	Development and validation of a disease-specific questionnaire on the quality of life of patients with chronic venous insufficiency. <i>Vasa - European Journal of Vascular Medicine</i> , 1997, 26, 291-301.	1.4	58
71	Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1162-1170.e3.	1.2	57
72	Quality of life and satisfaction of patients with leg ulcers - results of a community-based study. <i>Vasa - European Journal of Vascular Medicine</i> , 2011, 40, 131-138.	1.4	57

#	ARTICLE	IF	CITATIONS
73	S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus â€“ Update â€“ Kurzversion. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-873.	0.8	56
74	Compression therapy: scientific background and practical applications. JDDG - Journal of the German Society of Dermatology, 2014, 12, 794-801.	0.8	54
75	Time Needed for Treatment Is the Major Predictor of Quality of Life in Psoriasis. Dermatology, 2010, 221, 154-159.	2.1	53
76	Dimensions of patient needs in dermatology: subscales of the patient benefit index. Archives of Dermatological Research, 2011, 303, 11-17.	1.9	53
77	Development, validation and clinical use of the FLQA-I, a disease-specific quality of life questionnaire for patients with lymphedema. Vasa - European Journal of Vascular Medicine, 2005, 34, 31-35.	1.4	52
78	Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. British Journal of Dermatology, 2014, 170, 591-598.	1.5	51
79	Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patientâ€“Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1633-1643.	2.4	51
80	Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. JDDG - Journal of the German Society of Dermatology, 2015, 13, 674-689.	0.8	50
81	S2k guideline on diagnosis and treatment of atopic dermatitis â€“ short version. JDDG - Journal of the German Society of Dermatology, 2016, 14, 92-105.	0.8	49
82	Epidemiology of skin cancer in the German population: impact of socioeconomic and geographic factors. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1906-1913.	2.4	49
83	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. British Journal of Dermatology, 2017, 177, 1024-1032.	1.5	48
84	Costâ€“ofâ€“illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany. British Journal of Dermatology, 2011, 165, 845-851.	1.5	47
85	The German National Program on Psoriasis Health Care 2005â€“2015: results and experiences. Archives of Dermatological Research, 2016, 308, 389-400.	1.9	47
86	Global Allergy Forum and 3rd Davos Declaration 2015. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 588-592.	5.7	47
87	Efficacy, Tolerability and Patient Benefit of Ultrasound-Assisted Wound Treatment versus Surgical Debridement: A Randomized Clinical Study. Dermatology, 2011, 222, 244-249.	2.1	46
88	Realâ€“world evidence of secukinumab in psoriasis treatment â€“ a metaâ€“analysis of 43 studies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1174-1185.	2.4	46
89	Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 719-726.	2.4	45
90	Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. International Journal of Dermatology, 2016, 55, 296-302.	1.0	45

#	ARTICLE	IF	CITATIONS
91	Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2. <i>Journal of Dermatological Treatment</i> , 2011, 22, 337-347.	2.2	44
92	Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies. <i>Dermatology</i> , 2012, 224, 236-243.	2.1	43
93	Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 816-827.	2.4	43
94	Epidemiology of hidradenitis suppurativa in Germany – an observational cohort study based on a multisource approach. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 174-179.	2.4	43
95	Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis. <i>Dermatology</i> , 2009, 219, 54-58.	2.1	42
96	Quality of Care in Chronic Leg Ulcer in the Community: Introduction of Quality Indicators and a Scoring System. <i>Dermatology</i> , 2011, 222, 321-329.	2.1	42
97	A framework for improving the quality of care for people with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1-16.	2.4	42
98	Epidemiology and use of compression treatment in venous leg ulcers: nationwide claims data analysis in Germany. <i>International Wound Journal</i> , 2017, 14, 338-343.	2.9	42
99	Validity and feasibility of the wound-QoL questionnaire on health-related quality of life in chronic wounds. <i>Wound Repair and Regeneration</i> , 2017, 25, 852-857.	3.0	42
100	Novel TRPM8 agonist cooling compound against chronic itch: results from a randomized, double-blind, controlled, pilot study in dry skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1064-1068.	2.4	42
101	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. <i>British Journal of Dermatology</i> , 2019, 181, 358-365.	1.5	42
102	Quality of psoriasis care in Germany: results of the national health care study ‘PsoHealth’. <i>Archives of Dermatological Research</i> , 2016, 308, 401-408.	1.9	41
103	European EADV network on assessment of severity and burden of Pruritus (PruNet): first meeting on outcome tools. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1144-1147.	2.4	41
104	Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1263-1272.	2.4	41
105	Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE AD7 Phase 3 randomized trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1543-1552.	2.4	41
106	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905.	3.0	40
107	Nail psoriasis as a severity indicator: results from the PsoReal study. <i>Patient Related Outcome Measures</i> , 2011, 2, 1.	1.2	38
108	Cost-of-illness Analysis of Patients with Chronic Hand Eczema in Routine Care in Germany: Focus on the Impact of Occupational Disease. <i>Acta Dermato-Venereologica</i> , 2013, 93, 538-543.	1.3	38

#	ARTICLE	IF	CITATIONS
109	Barriers to guideline-compliant psoriasis care: analyses and concepts. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 569-575.	2.4	38
110	Stigma in visible skin diseases – a literature review and development of a conceptual model. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1493-1504.	2.4	38
111	Use of the WoundQoL instrument in routine practice: Feasibility, validity and development of an implementation tool. Wound Medicine, 2014, 5, 4-8.	2.7	37
112	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the <scp>TRANSIT</scp> randomized trial in moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2014, 170, 435-444.	1.5	37
113	Compression therapy – cross-sectional observational survey about knowledge and practical treatment of specialised and non-specialised nurses and therapists. International Wound Journal, 2017, 14, 1148-1153.	2.9	37
114	Praxis der Tele Dermatologie. JDDG - Journal of the German Society of Dermatology, 2018, 16, 6-57.	0.8	37
115	Implementation of dupilumab in routine care of atopic eczema: results from the German national registry <scp>TREAT</scp> germany. British Journal of Dermatology, 2020, 183, 382-384.	1.5	37
116	Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study*. British Journal of Dermatology, 2021, 184, 425-436.	1.5	36
117	Benefit Evaluation in Vitiligo Treatment: Development and Validation of a Patient-Defined Outcome Questionnaire. Dermatology, 2008, 217, 101-106.	2.1	35
118	Psoriasis registries worldwide: systematic overview on registry publications. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1100-1106.	2.4	35
119	Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. European Journal of Dermatology, 2004, 14, 107-113.	0.6	35
120	Benefit evaluation in the therapy of chronic wounds from the patients' perspective – development and validation of a new method. Wound Repair and Regeneration, 2012, 20, 8-14.	3.0	34
121	Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 142-152.	2.4	34
122	Quality of care for leg ulcers in the metropolitan area of Hamburg – a community-based study. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 495-502.	2.4	33
123	Therapy of psoriasis in childhood and adolescence – a German expert consensus. JDDG - Journal of the German Society of Dermatology, 2011, 9, 815-823.	0.8	32
124	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. Dermatology, 2016, 232, 640-647.	2.1	32
125	Patient-Reported Outcome Measures in Pruritus: A Systematic Review of Measurement Properties. Journal of Investigative Dermatology, 2017, 137, 2069-2077.	0.7	32
126	S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. JDDG - Journal of the German Society of Dermatology, 2018, 16, 806-813.	0.8	32



#	ARTICLE	IF	CITATIONS
127	Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 123-127.	2.4	32
128	Recurrent eczema herpeticum – a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1074-1079.	2.4	32
129	Live interactive teledermatology compared to in-person care – a systematic review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 733-745.	2.4	32
130	Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). British Journal of Dermatology, 2022, 187, 338-352.	1.5	32
131	Evaluation of Patient-relevant Outcomes of Lymphedema and Lipedema Treatment: Development and Validation of a New Benefit Tool. European Journal of Vascular and Endovascular Surgery, 2014, 47, 100-107.	1.5	31
132	Loss of Interface Pressure in Various Compression Bandage Systems over Seven Days. Dermatology, 2014, 229, 343-352.	2.1	31
133	Ingenol mebutate gel for actinic keratosis: The link between quality of life, treatment satisfaction, and clinical outcomes. Journal of the American Academy of Dermatology, 2015, 72, 816-821.	1.2	31
134	Topische Therapie bei Psoriasis vulgaris – ein Behandlungspfad. JDDG - Journal of the German Society of Dermatology, 2019, 17, 3-14.	0.8	31
135	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. British Journal of Dermatology, 2020, 182, 869-879.	1.5	31
136	Cost of illness of psoriasis – results of a German cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 174-180.	2.4	30
137	Epidemiology and dermatological comorbidity of seborrhoeic dermatitis: population-based study in 161 269 employees. British Journal of Dermatology, 2019, 181, 743-748.	1.5	30
138	Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1666-1671.	2.4	30
139	German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations. JDDG - Journal of the German Society of Dermatology, 2021, 19, 934-150.	0.8	30
140	Measurement of patient-relevant benefits in the treatment of chronic hand eczema – a novel approach. Contact Dermatitis, 2009, 61, 39-45.	1.4	29
141	Therapie der Psoriasis im Kindes- und Jugendalter - ein deutscher Experten-Konsens. JDDG - Journal of the German Society of Dermatology, 2011, 9, 815-824.	0.8	29
142	Topical long-term therapy of psoriasis with vitamin D <sub>3</sub> analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. JDDG - Journal of the German Society of Dermatology, 2014, 12, 667-682.	0.8	29
143	Deutsches Psoriasis-Register PsoBest: Zielsetzung, Methodik und Basisdaten. JDDG - Journal of the German Society of Dermatology, 2014, 12, 48-58.	0.8	29
144	Treatment goals in psoriasis routine care. Archives of Dermatological Research, 2015, 307, 445-449.	1.9	29

#	ARTICLE	IF	CITATIONS
145	A systematic review on methods used to evaluate patient preferences in psoriasis treatments. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1454-1464.	2.4	29
146	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). American Journal of Clinical Dermatology, 2017, 18, 273-280.	6.7	29
147	Chronic pruritus: evaluation of patient needs and treatment goals with a special regard to differences according to pruritus classification and sex. British Journal of Dermatology, 2017, 176, 363-370.	1.5	29
148	Double-Blind, Randomized, Intraindividual Comparison Study of the Efficacy of Prilocaine and Lidocaine in Tumescant Local Anesthesia. Dermatology, 2010, 221, 248-252.	2.1	28
149	Skin cancer screening in Germany - perception by the public. JDDG - Journal of the German Society of Dermatology, 2012, 10, 42-49.	0.8	28
150	Quimp (quality of life impairment): an addition to the quality of life lexicon. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e181-e182.	2.4	28
151	Strategies to reduce stigma related to visible chronic skin diseases: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2029-2038.	2.4	28
152	Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne. JDDG - Journal of the German Society of Dermatology, 2008, 6, 113-120.	0.8	27
153	Quality of Life Measures for Dermatology: Definition, Evaluation, and Interpretation. Current Dermatology Reports, 2012, 1, 148-159.	2.1	27
154	Processes of psoriasis health care in Germany – long-term analysis of data from the statutory health insurances. JDDG - Journal of the German Society of Dermatology, 2012, 10, 648-655.	0.8	27
155	Cost-effectiveness of treating vascular leg ulcers with UrgoStart <sup>®</sup> and UrgoCell <sup>®</sup> Contact. International Wound Journal, 2016, 13, 82-87.	2.9	27
156	Efficacy of Body Lotion Containing N-palmitoylethanolamine in Subjects with Chronic Pruritus due to Dry Skin: A Dermatocosmetic Study. Acta Dermato-Venereologica, 2017, 97, 639-641.	1.3	27
157	Social participation of people with chronic wounds: A systematic review. International Wound Journal, 2021, 18, 287-311.	2.9	27
158	Cost-Effectiveness Model of Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Germany. Dermatology, 2007, 215, 219-228.	2.1	26
159	Systemic treatment with corticosteroids in psoriasis – health care provision far beyond the S3 guidelines. JDDG - Journal of the German Society of Dermatology, 2011, 9, 833-838.	0.8	26
160	Dynamic Pruritus Score: Evaluation of the Validity and Reliability of a New Instrument to Assess the Course of Pruritus. Acta Dermato-Venereologica, 2017, 97, 230-234.	1.3	26
161	Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 318-324.	2.4	26
162	Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus?. British Journal of Dermatology, 2015, 172, 1669-1671.	1.5	25

#	ARTICLE	IF	CITATIONS
163	Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany. JDDG - Journal of the German Society of Dermatology, 2017, 15, 49-59.	0.8	25
164	The Woundâ€œQoL questionnaire on quality of life in chronic wounds is highly reliable. Wound Repair and Regeneration, 2017, 25, 730-732.	3.0	25
165	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. British Journal of Dermatology, 2018, 179, 1385-1391.	1.5	25
166	Secukinumab is effective in treatment of moderateâ€œtoâ€œsevere plaque psoriasis: realâ€œlife effectiveness and safety from the PROSPECT study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 310-318.	2.4	25
167	Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review. Journal of Wound Care, 2020, 29, 102-118.	1.2	25
168	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 123-134.	2.4	25
169	The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on nonâ€œlesional skin. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 738-743.	2.4	25
170	Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Archives of Dermatological Research, 2013, 305, 197-204.	1.9	24
171	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). British Journal of Dermatology, 2014, 170, 425-434.	1.5	24
172	Clinical course, treatment modalities, and quality of life in patients with congenital melanocytic nevi â€œ data from the German CMN registry. JDDG - Journal of the German Society of Dermatology, 2017, 15, 159-167.	0.8	24
173	Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1523-1529.	2.4	24
174	S2k guidelines for the treatment of psoriasis in children and adolescents â€œ Short version part 2. JDDG - Journal of the German Society of Dermatology, 2019, 17, 959-973.	0.8	24
175	Effects of psychosocial interventions on patientâ€œreported outcomes in patients with psoriasis: a systematic review and metaâ€œanalysis. British Journal of Dermatology, 2019, 181, 939-945.	1.5	24
176	S2k Guidelines for the diagnosis and treatment of chronic pruritus â€œ update â€œ short version. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-872.	0.8	23
177	Costâ€œofâ€œillness of melanoma in Europe â€œ a systematic review of the published literature. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 504-510.	2.4	23
178	Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study. Advances in Therapy, 2020, 37, 2865-2883.	2.9	23
179	Cumulative Life Course Impairment: Identifying Patients at Risk. Current Problems in Dermatology, 2013, 44, 74-81.	0.7	22
180	Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderateâ€œtoâ€œsevere psoriasis in five European countries. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1316-1323.	2.4	22

#	ARTICLE	IF	CITATIONS
181	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 741-748.	1.2	22
182	Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. <i>British Journal of Dermatology</i> , 2019, 181, 976-982.	1.5	22
183	Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*. <i>British Journal of Dermatology</i> , 2022, 186, 942-954.	1.5	22
184	Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 292-299.	2.4	21
185	Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis. <i>Dermatology</i> , 2010, 221, 236-242.	2.1	21
186	Clinical Features and Treatment Outcomes of Vitiligo from the Patients' Perspective: Results of a National Survey in Germany. <i>Dermatology</i> , 2010, 220, 194-200.	2.1	21
187	A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 665-670.	5.7	21
188	Positionspapier: Diagnostik und Therapie der Xerosis cutis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 3-35.	0.8	21
189	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study*. <i>British Journal of Dermatology</i> , 2021, 185, 1160-1168.	1.5	21
190	A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 228-236.	2.4	21
191	Characterization of Patient-Reported Outcomes in Moderate to Severe Psoriasis. <i>Dermatology</i> , 2011, 223, 80-86.	2.1	20
192	Allergies in Germany – prevalence and perception by the public. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 514-520.	0.8	20
193	Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study 'Atopic Health'. <i>Dermatology</i> , 2014, 228, 350-359.	2.1	20
194	Waiting time and practice organization in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 812-814.	0.8	20
195	Health economic analyses of psoriasis management: a systematic literature search. <i>Archives of Dermatological Research</i> , 2016, 308, 601-616.	1.9	20
196	Kompressionstherapie – Versorgungspraxis: Informationsstand von Patienten mit Ulcus cruris venosum. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1273-1283.	0.8	20
197	Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2191-2199.	2.4	20
198	Cost-of-illness of melanoma in Europe – a modelling approach. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 34-45.	2.4	20

#	ARTICLE	IF	CITATIONS
199	Atopic dermatitis shows significant cutaneous comorbidity: results from large-scale investigations in the working population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 135-141.	2.4	20
200	Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 431-440.	2.4	20
201	German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm "Part 2: Treatment monitoring and specific clinical or comorbid situations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1092-1115.	0.8	20
202	Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00403.	1.3	20
203	Früherkennung der Komorbidität bei Psoriasis: Konsensempfehlungen der Nationalen Konferenz zur Versorgung der Psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 674-690.	0.8	19
204	Ustekinumab in the treatment of palmoplantar pustular psoriasis " a case series of nine patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1108-1113.	0.8	19
205	Effectiveness of alitretinoin in severe chronic hand eczema: PASSION, a real-world observational study. <i>Journal of Dermatological Treatment</i> , 2016, 27, 577-583.	2.2	19
206	Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees. <i>Archives of Dermatological Research</i> , 2017, 309, 349-356.	1.9	19
207	Fear of cancer progression in patients with stage IA malignant melanoma. <i>European Journal of Cancer Care</i> , 2018, 27, e12901.	1.5	19
208	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e267-e269.	2.4	19
209	Perception and determinants of stigmatization of people with psoriasis in the German population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2846-2855.	2.4	19
210	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque Psoriasis treated with Biologics in a REAL world setting (PSO-BIO-REAL). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2566-2573.	2.4	19
211	Significance of chronic pruritus for intrapersonal burden and interpersonal experiences of stigmatization and sexuality in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1553-1561.	2.4	19
212	Cost of illness of atopic dermatitis in Germany: data from dermatology routine care. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1346-1356.	2.4	19
213	Validation of the disease-specific quality of life Wuerzburg Wound Score in patients with chronic leg ulcer. <i>Vasa - European Journal of Vascular Medicine</i> , 2014, 43, 372-379.	1.4	19
214	Inpatient care for skin diseases in Germany: multi-source analysis on the current and future health care needs. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 25-53.	0.8	19
215	Assessing the Value of Supportive Skin Care: Development and Validation of an Instrument for Evaluating Patient-Relevant Benefit. <i>Dermatology</i> , 2009, 218, 255-259.	2.1	18
216	How do regional factors influence psoriasis patient care in Germany?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 516-523.	0.8	18

#	ARTICLE	IF	CITATIONS
217	The impact of oral vitamin A derivatives on lipid metabolism – What recommendations can be derived for dealing with this issue in the daily dermatological practice?. JDDG - Journal of the German Society of Dermatology, 2011, 9, 600-606.	0.8	18
218	Gesetzliches Hautkrebscreening in Deutschland: Wahrnehmung in der Öffentlichkeit. JDDG - Journal of the German Society of Dermatology, 2012, 10, 42-50.	0.8	18
219	Nail psoriasis – a treatment challenge. JDDG - Journal of the German Society of Dermatology, 2013, 11, 203-220.	0.8	18
220	Patient Benefit Index (PBI) in the treatment of psoriasis – results of the National Care Study – PsoHealth. European Journal of Dermatology, 2013, 23, 212-217.	0.6	18
221	Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response – results of a phase II regimen-finding trial. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 645-649.	2.4	18
222	Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. Dermatology, 2016, 232, 655-663.	2.1	18
223	S2k guidelines for the use of topical preparations on the skin. JDDG - Journal of the German Society of Dermatology, 2018, 16, 376-392.	0.8	18
224	Education in people with venous leg ulcers based on a brochure about compression therapy: A quasi-randomised controlled trial. International Wound Journal, 2019, 16, 1252-1262.	2.9	18
225	S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 1. JDDG - Journal of the German Society of Dermatology, 2019, 17, 856-870.	0.8	18
226	Translating the WHO resolution in a member state: towards a German programme on – Destigmatization™ for individuals with visible chronic skin diseases. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2202-2208.	2.4	18
227	Validation of a Comprehensive Set of Pruritus Assessment Instruments: The Chronic Pruritus Tools Questionnaire PRURITOOLS. Acta Dermato-Venereologica, 2019, 99, 657-663.	1.3	18
228	Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis. Journal of the American Academy of Dermatology, 2021, 84, 60-69.	1.2	18
229	Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004–2017. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1536-1542.	2.4	18
230	Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases – a systematic review. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2166-2184.	2.4	18
231	Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1614-1621.	2.4	18
232	Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1092-1117.	0.8	18
233	Health Services Research in Psoriasis – The German Approach. Dermatology, 2009, 218, 293-301.	2.1	17
234	Systemische Glukokortikosteroide bei Psoriasis - Versorgung jenseits der S3-Leitlinie. JDDG - Journal of the German Society of Dermatology, 2011, 9, 833-839.	0.8	17

#	ARTICLE	IF	CITATIONS
235	Participation and health care provision of statutory skin cancer screening in Germany – a secondary data analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 424-427.	2.4	17
236	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. <i>PLoS ONE</i> , 2020, 15, e0235091.	2.5	17
237	Pruritus Intensity Scales across Europe: a prospective validation study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1176-1185.	2.4	17
238	Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). <i>British Journal of Dermatology</i> , 2022, 187, 866-877.	1.5	17
239	Predictors of the Quality of Life in Patients with Atopic Dermatitis. <i>Dermatology and Psychosomatics</i> , 2000, 1, 66-70.	0.1	16
240	Health care characteristics of basal cell carcinoma in Germany: the role of insurance status and socio-demographic factors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 803-811.	0.8	16
241	Quality of life measurement in chronic wounds and inflammatory skin diseases: Definitions, standards and instruments. <i>Wound Medicine</i> , 2014, 5, 29-38.	2.7	16
242	Importance of basic therapy in psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 415-418.	0.8	16
243	Patient-relevant needs and treatment goals in nail psoriasis. <i>Quality of Life Research</i> , 2016, 25, 1179-1188.	3.1	16
244	Perception and image of dermatology in the German general population 2002-2014. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2124-2130.	2.4	16
245	Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population-based claims data analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2270-2276.	2.4	16
246	Chronic venous leg ulcers: the future of cell-based therapies. <i>Lancet, The</i> , 2012, 380, 953-955.	13.7	15
247	Quality of life in patients with primary and secondary lymphedema in the community. <i>Wound Repair and Regeneration</i> , 2017, 25, 466-473.	3.0	15
248	Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 411-419.	2.4	15
249	Epidemiology of Vitiligo – A Dual Population-Based Approach. <i>Clinical Epidemiology</i> , 2021, Volume 13, 373-382.	3.0	15
250	Quality of Life in Different Stages of Chronic Venous Insufficiency and Leg Ulcer. <i>Dermatology and Psychosomatics</i> , 2002, 3, 126-131.	0.1	14
251	Use of topical steroids is largely restricted by irrational emotional concerns in both patients and physicians. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1560-1561.	5.7	14
252	Quality-of-life evaluation in chronic wounds: comparative analysis of three disease-specific questionnaires. <i>International Wound Journal</i> , 2017, 14, 1299-1304.	2.9	14

#	ARTICLE	IF	CITATIONS
253	Measurement of healthcare quality in atopic dermatitis – development and application of a set of quality indicators. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2237-2243.	2.4	14
254	Cumulative Life Course Impairment (CLCI): A new concept to characterize persistent patient burden in chronic wounds. <i>Wound Medicine</i> , 2013, 1, 2-6.	2.7	13
255	Biosimilars in psoriasis: What can we expect?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 306-312.	0.8	13
256	Validation of a short-form of the Freiburg Life Quality Assessment for lymphoedema (FLQA-LS) instrument. <i>British Journal of Dermatology</i> , 2018, 179, 1329-1333.	1.5	13
257	Development and psychometric evaluation of the U.S. English <scp>Woundâ€œQoL</scp> questionnaire to assess healthâ€œrelated quality of life in people with chronic wounds. <i>Wound Repair and Regeneration</i> , 2020, 28, 609-616.	3.0	13
258	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <i>Dermatology and Therapy</i> , 2020, 10, 1099-1109.	3.0	13
259	Influence of human wound exudate on the bactericidal efficacy of antiseptic agents in quantitative suspension tests on the basis of European Standards (DIN EN 13727). <i>International Wound Journal</i> , 2020, 17, 781-789.	2.9	13
260	A phase 4, randomized, headâ€œtoâ€œhead trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderateâ€œtoâ€œsevere plaque psoriasis (CHANGE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 701-711.	2.4	13
261	Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis. <i>JAAD International</i> , 2021, 2, 28-30.	2.2	13
262	Regional variations and prevalence of psoriasis in Germany from 2010 to 2017: a cross-sectional, spatio-epidemiological study on ambulatory claims data. <i>BMJ Open</i> , 2021, 11, e047806.	1.9	13
263	Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey. <i>Dermatology and Therapy</i> , 2022, 12, 1055-1064.	3.0	13
264	Versorgung der Akne vulgaris in Deutschland – Patientenbefragung in einem bundesweiten Apothekennetzwerk. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 1060-1064.	0.8	12
265	Welchen Einfluss haben regionale Faktoren auf die Versorgung der Psoriasis in Deutschland?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 516-524.	0.8	12
266	Influenza vaccination rate among patients with moderate to severe psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 837-844.	0.8	12
267	Drug supply for children with psoriasis in Germany. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 751-755.	0.8	12
268	Clinical management of pruritus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 101-114.	0.8	12
269	Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study. <i>Dermatology</i> , 2016, 232, 334-343.	2.1	12
270	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 294-303.	2.4	12



#	ARTICLE	IF	CITATIONS
271	S2â€œLeitlinie zum Gebrauch von PrÃ¶parationen zur lokalen Anwendung auf der Haut (Topika). JDDG - Journal of the German Society of Dermatology, 2018, 16, 376-392.	0.8	12
272	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 2019, 180, 894-901.	1.5	12
273	Economic evaluation of a tertiary prevention program for occupational skin diseases in Germany. Contact Dermatitis, 2020, 82, 361-369.	1.4	12
274	Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis. Clinical Epidemiology, 2021, Volume 13, 593-602.	3.0	12
275	Effects of Autologous Keratinocyte Transplantation on the Quality of Life of Patients with Severe Chronic Leg Ulcers. Dermatology and Psychosomatics, 2001, 2, 73-76.	0.1	11
276	Quality of medical care of patients with acne vulgaris in Germany Ã¢â€šâ„¢ nationwide survey of pharmacy clients. JDDG - Journal of the German Society of Dermatology, 2009, 7, 1060-1063.	0.8	11
277	Routine skin cancer screening in Germany: First data on the impact on health care in dermatology. JDDG - Journal of the German Society of Dermatology, 2010, 8, 674-680.	0.8	11
278	Randomized standard-of-care-controlled trial of a silica gel fibre matrix in the treatment of chronic venous leg ulcers. European Journal of Dermatology, 2014, 24, 210-216.	0.6	11
279	Association of atopy and tentative diagnosis of skin cancer â€œ results from occupational skin cancer screenings. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 2083-2087.	2.4	11
280	Review of health economic analyses in atopic dermatitis: how diverse is the literature?. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 127-145.	1.4	11
281	Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany. Journal of Dermatological Treatment, 2022, 33, 976-982.	2.2	11
282	Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Archives of Dermatological Research, 2021, 313, 95-99.	1.9	11
283	Assessing the quality of life of people with chronic wounds by using the crossâ€œculturally valid and revised <scp>Woundâ€™QoL</scp> questionnaire. Wound Repair and Regeneration, 2021, 29, 452-459.	3.0	11
284	Psychosocial Distress of Patients with Psoriasis: Protocol for an Assessment of Care Needs and the Development of a Supportive Intervention. JMIR Research Protocols, 2018, 7, e22.	1.0	11
285	Epidemiology of rosacea in a populationâ€œbased study of 161,269 German employees. International Journal of Dermatology, 2022, 61, 570-576.	1.0	11
286	New treatments and new assessment instruments for Hidradenitis suppurativa. Experimental Dermatology, 2022, 31, 33-39.	2.9	11
287	Does climate change affect the incidence of skin and allergic diseases in Germany?. JDDG - Journal of the German Society of Dermatology, 2008, 6, 632-638.	0.8	10
288	Routine Skin Cancer Screening in Germany: Four Years of Experience from the Dermatologists' Perspective. Dermatology, 2012, 225, 289-293.	2.1	10

#	ARTICLE	IF	CITATIONS
289	Cumulative Life Course Impairment in Chronic Wounds. <i>Current Problems in Dermatology</i> , 2013, 44, 125-129.	0.7	10
290	Compression therapy – current practice of care: level of knowledge in patients with venous leg ulcers. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1273-1282.	0.8	10
291	Impact on quality of life of alitretinoin in severe chronic hand eczema: FUGETTA real-world study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1261-1270.	0.8	10
292	Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>British Journal of Dermatology</i> , 2018, 179, 984-986.	1.5	10
293	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 267-278.	0.6	10
294	Nutritional status and quality of nutrition in chronic wound patients. <i>International Wound Journal</i> , 2020, 17, 1246-1254.	2.9	10
295	Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2548-2556.	2.4	10
296	Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 403-412.	2.4	10
297	Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study. <i>Acta Dermato-Venereologica</i> , 2021, 102, adv00660.	1.3	10
298	S1 Guideline: Diagnosis and therapy of vitiligo. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 365-378.	0.8	10
299	Quality of Care of Patients with Chronic Lymphoedema in Germany. <i>Dermatology</i> , 2013, 226, 238-246.	2.1	9
300	Leistungsprofile der Deutschen Universitäts-Hautkliniken. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 170-177.	0.8	9
301	FR10460...Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 603.2-604.	0.9	9
302	Patient benefits in the treatment of psoriasis: long-term outcomes in German routine care 2007-2014. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1829-1833.	2.4	9
303	What is psoriasis? - Perception and assessment of psoriasis among the German population. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 703-710.	0.8	9
304	Disease burden and patient needs and benefits in anogenital psoriasis: developmental specificities for person-centred healthcare of emerging adults and adults. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1010-1018.	2.4	9
305	Lymphedema - the long way to diagnosis and therapy. <i>Vasa - European Journal of Vascular Medicine</i> , 2013, 42, 363-369.	1.4	9
306	Population-Based Epidemiologic Study in Venous Diseases in Germany – Prevalence, Comorbidity, and Medical Needs in a Cohort of 19,104 Workers. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 679-687.	2.3	9

#	ARTICLE	IF	CITATIONS
307	Assessment of stigma related to visible skin diseases: a systematic review and evaluation of patient-reported outcome measures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 499-525.	2.4	9
308	Das Hautkrebscreening als Regelleistung der gesetzlichen Krankenkassen: Erste Daten zu den Auswirkungen auf die dermatologische Versorgung. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 674-680.	0.8	8
309	Development and use of guideline-derived quality indicators for community lymphoedema. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 227-234.	2.4	8
310	Drug supply for psoriasis – results from a national pharmacy network. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 638-643.	0.8	8
311	Patient-reported outcomes as diagnostic tools and clues in chronic wounds: Considerations for practice. <i>Wound Medicine</i> , 2015, 8, 6-14.	2.7	8
312	Analysis of patients' willingness to be mobile, taking into account individual characteristics and two exemplary indications. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 430-438.	0.8	8
313	Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. <i>Value in Health</i> , 2017, 20, 1174-1179.	0.3	8
314	Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross-sectional survey. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 981-990.	0.8	8
315	The value of subcutaneous vs. oral methotrexate: real-world data from the German psoriasis registry PsoBest. <i>British Journal of Dermatology</i> , 2021, 184, 765-767.	1.5	8
316	Validación de la versión española del cuestionario Wound-QoL. <i>Actas Dermo-sifiliográficas</i> , 2021, 112, 44-51.	0.4	8
317	Documentation of psoriasis in routine care – expert consensus on a German data set. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1463-1475.	0.8	8
318	Atopic dermatitis: disease characteristics and comorbidities in smoking and non-smoking patients from the TREATgermany registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 413-421.	2.4	8
319	The Role of Health Literacy among Outpatient Caregivers during the COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11743.	2.6	8
320	Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 3-16.	2.4	8
321	The German national consensus on wound documentation and outcomes: Rationale, working programme and current status. <i>Wound Medicine</i> , 2014, 7, 8-13.	2.7	7
322	Continued treatment with secukinumab is associated with high retention or regain of response. <i>British Journal of Dermatology</i> , 2019, 182, 67-75.	1.5	7
323	How should electronic health records be designed? A cross-sectional study in patients with psoriasis. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 218.	3.0	7
324	Poor Adherence to International Cancer Prevention Recommendations Among Patients With Prostate Cancer: First Results From the MARTINI-Lifestyle Cohort. <i>European Urology Focus</i> , 2020, 6, 935-940.	3.1	7

#	ARTICLE	IF	CITATIONS
325	Regional variations in the use of statutory skin cancer screenings in Germany: population-based spatial multisource analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1736-1743.	2.4	7
326	Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study. <i>Advances in Therapy</i> , 2020, 37, 2932-2945.	2.9	7
327	Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1-11.	3.0	7
328	Effectiveness of a structured short intervention against stigmatisation in chronic visible skin diseases: Results of a controlled trial in future educators. <i>Health Expectations</i> , 2021, 24, 1790-1800.	2.6	7
329	Influence of learning disabilities on the tumour predisposition syndrome NF1-survey from adult patients' perspective. <i>Anticancer Research</i> , 2014, 34, 3675-81.	1.1	7
330	Epidemiology of skin diseases in Germany: systematic review of the current state of research – part 1: cutaneous tumor diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 257-270.	0.8	7
331	Long-Term Treatment with Dimethyl Fumarate for Plaque Psoriasis in Routine Practice: Good Overall Effectiveness and Positive Effect on Impactful Areas. <i>Dermatology and Therapy</i> , 2022, 12, 1121-1131.	3.0	7
332	Attitudes and Experiences towards Corticoid Treatment among Parents of Children with Atopic Dermatitis. <i>Dermatology and Psychosomatics</i> , 2000, 1, 155-161.	0.1	6
333	Health services research in dermatology ? current update and perspectives. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 482-487.	0.8	6
334	Internet-supported gathering of treatment data and patient benefits in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 541-547.	2.4	6
335	Stellenwert der Basistherapie bei Psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 415-418.	0.8	6
336	Differences in patient and physician assessment of a dynamic patient reported outcome tool for chronic pruritus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 962-965.	2.4	6
337	Der Einfluss von Alitretinoin auf die Lebensqualität bei Patienten mit schwerem chronischen Handekzem: FUGETTA – Beobachtungsstudie unter Praxisbedingungen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1261-1272.	0.8	6
338	The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach. <i>Quality of Life Research</i> , 2016, 25, 447-455.	3.1	6
339	Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria. <i>European Journal of Dermatology</i> , 2020, 30, 259-266.	0.6	6
340	Determinants of costs and benefits in psoriasis routine care: results from a cross-sectional nationwide study in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e63-e65.	2.4	6
341	Epidemiology, Comorbidity and Risk Factors for Psoriatic Arthritis: A Health Insurance Claims Database Analysis. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00566.	1.3	6
342	Adherence to Guideline-Oriented Preventive Measures in Patients with Atopic Dermatitis in Germany. <i>Dermatology</i> , 2022, 238, 307-312.	2.1	6

#	ARTICLE	IF	CITATIONS
343	The Health Behaviour of German Outpatient Caregivers in Relation to Their Working Conditions: A Qualitative Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5942.	2.6	6
344	Status quo und Perspektiven der Hautkliniken in Deutschland: Versorgungsspektren und Personalsituation. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 14-24.	0.8	6
345	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. <i>Dermatology and Therapy</i> , 2022, 12, 81-95.	3.0	6
346	Psoriasis comorbidities in Germany: A population-based study on spatiotemporal variations. <i>PLoS ONE</i> , 2022, 17, e0265741.	2.5	6
347	S2-Guideline for Tele dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, , .	0.8	6
348	Epidemiology of skin diseases in Germany: systematic review of the current state of research – part 2: non-infectious skin diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 445-455.	0.8	6
349	Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the <scp>SERENA</scp> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1796-1804.	2.4	6
350	Measurement properties of patient-reported outcome measures for pruritus: An updated systematic review. <i>Journal of Investigative Dermatology</i> , 2021, , .	0.7	5
351	The Health Behaviour of German Outpatient Caregivers in Relation to the COVID-19 Pandemic: A Mixed-Methods Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8213.	2.6	5
352	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. <i>Advances in Therapy</i> , 2021, 38, 5253-5269.	2.9	5
353	Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort. <i>European Urology Focus</i> , 2021, 7, 973-979.	3.1	5
354	Stationäre Versorgung von Hautkrankheiten in Deutschland: Multi-Source-Analyse zum aktuellen und zukünftigen Bedarf. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 25-54.	0.8	5
355	Strukturen und Leistungsmerkmale der Hautkliniken in Deutschland: Aktuelle Bestandsaufnahme und Langzeitverlauf. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 5-13.	0.8	5
356	A Structured Intervention for Medical Students Significantly Improves Awareness of Stigmatisation in Visible Chronic Skin Diseases: A Randomised Controlled Trial. <i>Acta Dermato-Venereologica</i> , 2021, 102, adv00641.	1.3	5
357	Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 41-48.	0.6	5
358	Ustekinumab in der Therapie der Pustulosis palmoplantaris – Eine Fallserie mit neun Patienten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1109-1115.	0.8	4
359	Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data. <i>European Journal of Health Economics</i> , 2017, 18, 181-193.	2.8	4
360	Rapid improvement of psoriasis in a patient with lung cancer after treatment with erlotinib. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e311-e313.	2.4	4

#	ARTICLE	IF	CITATIONS
361	Benefits of a membership in a psoriasis patient organisation: a quasi-experimental longitudinal study. Archives of Dermatological Research, 2018, 310, 807-813.	1.9	4
362	How to weight patient-relevant treatment goals for assessing treatment benefit in psoriasis: preference elicitation methods vs. rating scales. Archives of Dermatological Research, 2018, 310, 567-577.	1.9	4
363	Was ist Schuppenflechte? - Wahrnehmung und Bewertung der Psoriasis in der deutschen Bevölkerung. JDDG - Journal of the German Society of Dermatology, 2018, 16, 703-710.	0.8	4
364	Modelling first-year cost of illness of melanoma attributable to sunbed use in Europe. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 46-56.	2.4	4
365	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate to severe plaque psoriasis naïve to systemic treatment. British Journal of Dermatology, 2021, 184, 548-550.	1.5	4
366	Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. Journal of Dermatological Treatment, 2022, 33, 1511-1520.	2.2	4
367	Development of a model to predict closure of chronic wounds in Germany: Claims data analysis. International Wound Journal, 2022, 19, 76-85.	2.9	4
368	Determining the Minimal Important Difference for the Wound-QoL Questionnaire. Patient Preference and Adherence, 2021, Volume 15, 1571-1578.	1.8	4
369	Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments. American Journal of Clinical Dermatology, 2021, 22, 747-755.	6.7	4
370	Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2398-2408.	2.4	4
371	Network meta-analyses in psoriasis: overview and critical discussion. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2367-2376.	2.4	4
372	Exploring the burden of xerosis cutis and the impact of dermatological skin care from patient's perspective. Journal of Dermatological Treatment, 2022, 33, 2482-2487.	2.2	4
373	Development and validation of the Patient Benefit Index for peripheral arterial disease. Vasa - European Journal of Vascular Medicine, 2018, 47, 219-226.	1.4	4
374	Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 573-581.	2.4	4
375	Policy decision making and outcomes research in drug utilization. Zeitschrift Fur Gesundheitswissenschaften, 2005, 13, 257-264.	1.6	3
376	Development and validation of the Patient Benefit Index for the dermatocosmetic treatment of aged skin. Archives of Dermatological Research, 2016, 308, 319-324.	1.9	3
377	Decreasing sunbed use in the German population between 2001 and 2015: survey in 155,679 working persons. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 541-545.	2.4	3
378	Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire. Multiple Sclerosis and Related Disorders, 2019, 28, 256-261.	2.0	3

#	ARTICLE	IF	CITATIONS
379	Validation of the Spanish Wound-QoL Questionnaire. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 44-51.	0.4	3
380	Increasing competence in compression therapy for venous leg ulcers through training and exercise measured by a newly developed score—Results of a randomised controlled intervention study. <i>Wound Repair and Regeneration</i> , 2021, 29, 261-269.	3.0	3
381	Skin Lesions, Skin Care, and Characteristics of Pruritus in Patients Undergoing Haemodialysis. <i>Skin Pharmacology and Physiology</i> , 2022, 35, 87-93.	2.5	3
382	Development and validation of an outcome instrument measuring dry skin – the Xerosis Area and Severity Index (XASI). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	3
383	Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	3
384	Prevalence and Associated Diseases of Seborrheic Skin in Adults. <i>Clinical Epidemiology</i> , 2021, Volume 13, 845-851.	3.0	3
385	Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study. <i>Immunotherapy</i> , 2021, 13, 1193-1204.	2.0	3
386	Attitudes towards using electronic health records of patients with psoriasis and dermatologists: a cross-sectional study. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 344.	3.0	3
387	Workplace Health Promotion and COVID-19 Support Measures in Outpatient Care Services in Germany: A Quantitative Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12119.	2.6	3
388	Epidemiologie von Hautkrankheiten in Deutschland: systematische Literaturanalyse des aktuellen Forschungsstands – Teil 1: Tumorerkrankungen der Haut. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 257-271.	0.8	3
389	Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form. <i>British Journal of Dermatology</i> , 2022, 187, 588-589.	1.5	3
390	Determinants of costs and benefits in atopic dermatitis routine care in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1450-1455.	2.4	3
391	Patient–physician (dis)agreement on their reports of body surface area affected by psoriasis and its associations with disease burden. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	3
392	Making proper judgement when choosing a treatment for actinic keratosis. <i>Expert Review of Dermatology</i> , 2013, 8, 595-603.	0.3	2
393	Cost-Effectiveness of Secukinumab as First Biologic Treatment for Psoriasis Compared with Initiating Other Biologic Therapy in Germany. <i>Value in Health</i> , 2016, 19, A568-A569.	0.3	2
394	Quality of life in psoriasis. , 2016, , 101-116.		2
395	Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. <i>Acta Dermato-Venereologica</i> , 2017, 97, 516-518.	1.3	2
396	Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2313-2318.	2.4	2

#	ARTICLE	IF	CITATIONS
397	Sunbeds: An international common concern. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 5-5.	2.4	2
398	An indirect comparison of long-term efficacy of every 2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12. British Journal of Dermatology, 2020, 183, 52-59.	1.5	2
399	Documenting Patient Data in Psoriasis Clinical Practice – Patient Focus Groups Supporting Psoriasis Experts' Decision-making. Patient Preference and Adherence, 2021, Volume 15, 549-557.	1.8	2
400	Pharmacoeconomics of Occupational Diseases. , 2012, , 19-26.		2
401	Status quo and perspectives of dermatology hospitals in Germany: spectra of health care and staff situation. JDDG - Journal of the German Society of Dermatology, 2021, 19, 14-23.	0.8	2
402	Structures and performance characteristics of dermatology hospitals in Germany. Current status and long-term development. JDDG - Journal of the German Society of Dermatology, 2021, 19, 5-12.	0.8	2
403	How do dermatologists' personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast). British Journal of Dermatology, 2022, , .	1.5	2
404	Healthcare Utilization and Treatment Patterns in Patients with Chronic Prurigo and Chronic Pruritus in Germany. Dermatology, 2022, 238, 753-761.	2.1	2
405	Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review. Skin Health and Disease, 0, , .	1.5	2
406	Measuring well-being in psoriasis: psychometric properties of the WHO-5 questionnaire. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	2
407	The Value of Indirect Comparisons of Systemic Biologics for Psoriasis: Interpretation of Efficacy Findings. Dermatology and Therapy, 2022, 12, 1711-1727.	3.0	2
408	The Definition and Role of Quality of Life In Germany's Early Assessment of Drug Benefit. Value in Health, 2014, 17, A444.	0.3	1
409	Measuring Change in Quality of Life: Can We Distinguish Recall Bias and Scale Recalibration?. Value in Health, 2014, 17, A575.	0.3	1
410	Methodological Requirements Regarding Quality of Life Measurement in the Early Assessment of Benefit In Germany. Value in Health, 2014, 17, A437.	0.3	1
411	Comparative Effectiveness of An Acellular Synthetic Matrix As An Adjunct to Standard Care In The Treatment of Venous And Mixed Leg Ulcers: Modeling of Clinical Data And Routine Data. Value in Health, 2014, 17, A604.	0.3	1
412	Arbeitsgemeinschaft Dermatologische Onkologie (ADO). JDDG - Journal of the German Society of Dermatology, 2015, 13, 730-731.	0.8	1
413	Arzneimittelsicherheit bei Psoriasis: Welche Rolle spielt Suizidalität?. JDDG - Journal of the German Society of Dermatology, 2017, 15, 353-355.	0.8	1
414	Wound dressings for leg ulcers in Germany: Distribution, regional variations and health care providers. Wound Medicine, 2018, 23, 58-63.	2.7	1



#	ARTICLE	IF	CITATIONS
415	Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany. International Journal of Environmental Research and Public Health, 2020, 17, 440.	2.6	1
416	Efficacious psoriasis treatment improves patients' work productivity. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e593-e596.	2.4	1
417	Psychometric properties of the short version of the Freiburg Life Quality Assessment for chronic venous disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 139-145.e1.	1.6	1
418	Patient Needs and Treatment Goals in Clinical Care of Chronic Pruritus. , 2016, , 111-116.		1
419	Atopic dermatitis and depressive symptoms. Results of the German national AD Registry TREATgermany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
420	Effects of workplace skin cancer screenings on preventive and risk behaviour. Zeitschrift Fur Gesundheitswissenschaften, 2022, 30, 2243-2251.	1.6	1
421	Health-Related QOL Differs by Race/Ethnicity in North American Patients with Psoriasis: Results from PSOLAR. Journal of Investigative Dermatology, 2022, 142, 2528-2531.e3.	0.7	1
422	Clinical evaluation of UrgoStart Plus dressings in real-life conditions: results of a prospective multicentre study on 961 patients. Journal of Wound Care, 2021, 30, 966-978.	1.2	1
423	The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life. International Journal of MS Care, 2022, 24, 147-153.	1.0	1
424	Registries, multicentre and genome-wide association studies in hidradenitis suppurativa. Experimental Dermatology, 2022, 31, 22-28.	2.9	1
425	Methods Used To Measure Patient Preferences In Psoriasis Treatments – An Overview With Regards To The German Iqwig And G-Ba. Value in Health, 2014, 17, A574.	0.3	0
426	AB0743 – Low rates of major adverse cardiac events, malignancies, and serious infections in patients with psoriasis and psoriatic arthritis treated with apremilast for 156 weeks: pooled analysis from the esteem and palace 1-3 phase 3 trials. , 2017, , .		0
427	Lebensqualität und Behandlungsziele bei Psoriasis aus Patientensicht: Ergebnisse eines Österreichweiten Querschnitts-Survey. JDDG - Journal of the German Society of Dermatology, 2018, 16, 981-991.	0.8	0
428	Sunbed use in Europe: Time for information. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 3-3.	2.4	0
429	Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2241-2249.	2.4	0
430	Pharmacoeconomics of Occupational Diseases. , 2018, , 1-10.		0
431	Pharmacoeconomics of Occupational Diseases. , 2020, , 27-36.		0
432	Lebensqualität. , 2020, , 383-387.		0

#	ARTICLE	IF	CITATIONS
433	Gesundheitsökonomie und personenzentrierte Versorgung chronischer Wunden in Deutschland. , 2020, , 419-428.		0
434	Digital Health meets Hamburg integrated medical degree program iMED: concept and introduction of the new interdisciplinary 2 track Digital Health. GMS Journal for Medical Education, 2020, 37, Doc61.	0.1	0
435	Epidemiology of skin diseases in Germany: systematic review of the current state of research “ part 3: infectious skin diseases. JDDG - Journal of the German Society of Dermatology, 2022, , .	0.8	0
436	Epidemiologie von Hautkrankheiten in Deutschland: systematische Literaturanalyse des aktuellen Forschungsstands “ Teil 2: nichtinfektiöse Hauterkrankungen. JDDG - Journal of the German Society of Dermatology, 2022, 20, 445-457.	0.8	0
437	Development and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy. Journal of Asthma and Allergy, 2022, Volume 15, 611-621.	3.4	0
438	Development and validation of a disease-specific quality of life questionnaire for patients with peripheral artery disease (QOLPAD). Journal of Patient-Reported Outcomes, 2022, 6, .	1.9	0